<DOC>
	<DOCNO>NCT00034216</DOCNO>
	<brief_summary>This study collect blood patient cancer study level cell decrease immune response ( suppressor cell ) chemotherapy . Patients 18 year age old cancer may participate . This study involve treatment . Participants 50 ml ( 3 tablespoonful ) blood drawn . Depending condition , patient may invite enroll clinical research study involve chemotherapy , radiotherapy , surgery . Additional 40-ml blood sample may draw course treatment .</brief_summary>
	<brief_title>Collection Blood From Patients With Cancer</brief_title>
	<detailed_description>Background : - Correlative study perform biospecimens human subject use investigate biology solid tumor , inform development new strategy treat cancer , evaluate new therapeutic approach . Specific area interest include , limited : - underlie mechanisms tumor-specific immune response suppression cancer patient - genetic molecular profiling tumor circulate tumor cell ( cTC ) , circulate DNA , tissue analysis - investigation potential early diagnostic prognostic indicator solid tumor cTCs miRNA expression serum exosomes - identification mechanism drug-related adverse event correlation clinical parameter - role commensal gut microbiota innate adaptive response tumor well use anticancer agent Objectives : - Analyze biospecimens tissue , urine , saliva , stool blood component , include serum , leukocytes , peripheral blood mononuclear cell ( PBMC ) , circulate tumor cell ( cTC ) , human subject . - Correlate analysis result clinical parameter demographic , toxicity , treatment outcome . - Undertake genetic analysis prokaryotic eukaryotic sample advance mutational analysis . Eligibility : - Patients healthy volunteer whose biospecimens interest NIH investigator . - 18 year age old . Design : - Subject case evaluate NCI Interventional Radiology , NIH Clinical Center personnel . Blood , tissue , urine , saliva sample may collect initial visit follow-up visit .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients 18 year age old eligible . Patients must performance status ECOG 0 , 1 , 2 , 3 admission protocol . INCLUSION FOR APHERESIS : Hemoglobin great equal 10 mg/dL platelet count &gt; 75,000/mm ( 3 ) Weight great 25 kg HIV negative Prothrombin Time within normal limit Partial Thromboplastin Time within normal limit Medically indicated central line place adequate peripheral venous access EXCLUSION CRITERIA : Children eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 30, 2016</verification_date>
	<keyword>Suppressor Cells</keyword>
	<keyword>T-cells</keyword>
	<keyword>CD4+/CD25+ Cells</keyword>
	<keyword>Cancer</keyword>
	<keyword>Malignancy</keyword>
	<keyword>Blood Sample</keyword>
</DOC>